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Abstract: Diabetes mellitus is a signiﬁ  cant worldwide health problem, with the incidence of 
type 2 diabetes increasing at alarming rates. Insulin resistance and dysregulated blood glucose 
control are established risk factors for microvascular complications and cardiovascular disease. 
Despite the recognition of diabetes as a major health issue and the availability of a growing 
number of medications designed to counteract its detrimental effects, real and perceived barriers 
remain that prevent patients from achieving optimal blood glucose control. The development 
and utilization of inhaled insulin as a novel insulin delivery system may positively inﬂ  uence 
patient treatment adherence and optimal glycemic control, potentially leading to a reduction in 
cardiovascular complications in patients with diabetes.
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Introduction
Diabetes mellitus is a chronic disease resulting from an inability of the pancreas to 
produce enough of the regulatory hormone insulin and/or from ineffective systemic 
use of the insulin that it does produce (WHO 2006). One result of insulin insufﬁ  -
ciency is hyperglycemia, or elevated blood glucose (BG), a cardinal manifestation 
of uncontrolled diabetes that is indicative of a loss of normal metabolic homeostasis. 
Over time, hyperglycemia and its secondary effects negatively impact both macro- and 
microvascular targets, resulting variably in cardiovascular disease, stroke, blindness, 
renal failure, peripheral nerve damage, changes in the skin and joints, lower limb 
amputations, and premature death (The DCCT/EDIC Research Group 2000; Roglic 
et al 2005; Yach et al 2006).
The WHO estimates that more than 180 million people worldwide have diabetes 
(WHO 2006). This number is likely to more than double by 2030 (Wild et al 2004). 
In 2000, an estimated 2.9 million deaths worldwide were attributable to diabetes 
(Roglic et al 2005; WHO 2006). It is also estimated that 60% of all cases of diabe-
tes can be directly attributed to obesity (Yach et al 2006). With a global rise in the 
incidence of obesity, the societal and economic impact of diabetes will only increase 
without effective intervention (Centers for Disease Control and Prevention 2005; 
Yach et al 2006).
Glycosylated hemoglobin (HbA1c) is the most commonly used surrogate measure of 
average BG concentration over the life of the red blood cell (approximately 3 months). 
Subcutaneous administration of insulin is currently the primary mechanism for regulat-
ing HbA1c levels in patients who are severely insulin deﬁ  cient (type 1 diabetes mellitus, 
T1DM) and in patients with insulin resistance and/or an insufﬁ  cient insulin supply 
in whom lifestyle changes and/or oral anti-diabetic medications (OAMs) fail to elicit 
adequate metabolic response (type 2 diabetes mellitus, T2DM).
Initial insulin management of T2DM typically involves initiation of a single injection 
of long acting insulin (American Diabetes Association 2007). Although this treatment Vascular Health and Risk Management 2007:3(6) 948
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may allow nearly 60% of subjects to achieve target BG 
control with an HbA1c value below 7% (Riddle et al 2003, 
2006), this level of control is difﬁ  cult to achieve in broad 
clinical practice using basal-only therapy, and additional 
strategies to intensify therapy may be needed.
Intensiﬁ  cation of diabetes management often involves 
multiple (3 or more) daily injections of insulin and frequent 
BG monitoring (Diabetes Control and Complications Trial 
Research Group 1993; Schaumberg et al 2005). Although 
intensive management can prove effective in controlling 
HbA1c levels and reducing the risk of diabetes complications 
(Diabetes Control and Complications Trial Research Group 
1993), many patients with diabetes are reluctant to initiate 
or adhere to insulin therapy due to anxiety over multiple 
injections, inconvenience and social stigma (Hauber et al 
2005; White 2006).
The last 20 years has seen a revolution in research and 
development of alternative, injection-free insulin delivery 
methods. One of the most promising of these noninvasive 
candidates is inhaled insulin. In this article, we review the 
importance of insulin-mediated glycemic control in the 
prevention of diabetes-related cardiovascular disease, 
the development and current status of inhaled insulin as 
a novel drug delivery system, and the future potential 
of inhaled insulin as an effective therapy for reducing 
cardiovascular morbidity and mortality resulting from 
uncontrolled BG.
Overview of diabetes
and cardiovascular disease
There is a strikingly high incidence of cardiovascular-related 
morbidity and mortality in individuals with diabetes; approxi-
mately 50% of all diabetes-related deaths are attributed to 
coronary artery disease (Jelesoff et al 1996). This ﬁ  nding 
is not surprising, considering the multiple mechanisms by 
which insulin and circulating glucose regulate normal car-
diovascular function. Indeed, systemic changes related to 
chronic hyperglycemia directly contribute to the development 
of hypertension, atherosclerosis, thrombolytic events, and 
cardiomyopathy (King and Wakasaki 1999; Stenina 2005b; 
Watala 2005; Yamagishi and Imaizumi 2005; Ahmed and 
Goldstein 2006; Raman et al 2007).
Although much progress has been made in recent years, 
the mechanistic relationship between insulin resistance, 
hyperglycemia and the broad spectrum of diabetic compli-
cations remains an area of active research. Aspects of this 
ﬁ  eld of study have been reviewed by many investigators 
(King and Wakasaki 1999; Saltiel and Kahn 2001; Brownlee 
2005; Stenina 2005a) and will not be comprehensively 
reviewed here.
Diabetes can arise from a number of initiating conditions 
that collectively lead to common downstream outcomes 
(Figure 1). At the cellular level, a variety of cell types develop 
altered sensitivity to insulin through little known mechanisms 
(Saltiel and Kahn 2001; Brownlee 2005; Yamagishi and 
Imaizumi 2005). Specifically, insulin docking with the 
insulin receptor on the target cell surface normally activates 
multiple cascades of intracellular signaling. In insulin resis-
tance, one key pathway that includes the signaling kinases 
phosphatidylinositol-3-kinase and AKT fails to activate, 
disrupting normal intracellular insulin responsiveness and 
preventing key proteins involved in glucose uptake from 
being upregulated by insulin. As a result, cellular uptake 
of glucose is attenuated, circulating BG remains high, 
and tissues such as the endothelial lining of blood vessels 
passively accumulate glucose.
This rise in intracellular glucose increases glycolysis 
through the hexosamine metabolic pathway, damages cel-
lular proteins and mitochondria through the accumulation of 
advanced glycation end products, and creates intracellular 
oxidative stress. The net effect of these changes is altered 
gene transcription and protein production, leading to a pro-
gressive impairment of normal cell function (Saltiel and Kahn 
2001; Brownlee 2005; Yamagishi and Imaizumi 2005).
These progressive changes in normal cell and tissue 
function can lead to a spectrum of complications in patients 
with diabetes, including altered metabolism involving a shift 
from mixed glucose and fat use for energy production to 
the use of solely one or the other, altered vascular tone and 
responsiveness leading to hypertension, and altered produc-
tion and/or secretion of proteins involved in vasorelaxation, 
inﬂ  ammation, and coagulation (Figure 1). As a result, patients 
with diabetes can develop vascular disorders that may result 
in blindness, kidney disease and renal failure, loss of limbs 
from poor peripheral circulation, and blood vessel-occluding 
plaques and blood clots, leading to heart attacks and stroke 
(American Diabetes Association 2007).
Support for both elevated BG and endothelial cell oxi-
dative stress as contributors to these processes is mounting. 
Recent evidence that these factors are both interrelated and 
co-contributors to diabetes disease processes comes from 
reports that intensive glycemic control reduces circulating 
levels of markers of inﬂ  ammation (Schaumberg et al 2005) 
and normalizes endothelial function in patients with T1DM 
through the simultaneous control of hyperglycemia and 
oxidative stress (Ceriello et al 2007). Improved integrative Vascular Health and Risk Management 2007:3(6) 949
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Figure 1 Summary of diabetes causes and progression. Diabetes represents a collection of disease processes involving progressive systemic loss of tissue sensitivity to 
insulin signaling and/or the loss of pancreatic β-cell number or function. Changes at the level of intracellular signaling include decreased expression of glucose transport 
proteins (GLUT4), decreased production of endothelial vasodilators (nitric oxide), increased intracellular oxidative stress (O2-), and release into the systemic circulation of 
pro-inﬂ  ammatory (C-reactive protein, IL-6, TNFa) and coagulation (PAI-1, ICAM-1) mediators. These changes are both caused by and lead to decreased glucose absorp-
tion in several organs, increased levels of both circulating glucose (hyperglycemia) and non-esteriﬁ  ed fatty acids (dyslipidemia), passive glucose diffusion into cells with 
unregulated glucose uptake, changes in vascular endothelial tone, and formation of atherosclerotic plaques. Glycosylation of intracellular and systemically circulating proteins, 
increased luminal fatty acid deposition, altered cellular metabolism, and increased clotting contribute to an increased risk for the microvascular and macrovascular risks 
associated with uncontrolled diabetes.Vascular Health and Risk Management 2007:3(6) 950
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approaches to diabetes therapy may come from these lines of 
investigation, but presently, achieving normal BG regulation 
remains a primary therapeutic goal in diabetes.
Importance of controlling HbA1c, 
fasting blood glucose
and postprandial blood glucose
The central element in the development and progression of 
diabetes is the progressive loss of insulin production and/or 
insulin sensitivity, leading to dysregulation of systemic 
glucose utilization and increased BG concentrations. This 
rise in BG results in an increase in the covalent addition of 
glucose and its degradation products to both intracellular 
and circulating proteins (such as hemoglobin), which can 
contribute to altered vascular tone and atherosclerosis. Large 
clinical trials have demonstrated a direct correlation between 
HbA1c concentration and cardiovascular disease and mortality 
(Khaw et al 2004). Fasting BG concentration and postpran-
dial BG (PPBG) concentration are also used as indicators 
of effective short term BG regulation. Whereas fasting BG 
has long been used as a rapid indicator of insulin sufﬁ  ciency, 
PPBG is thought to provide separate evidence of a person’s 
ability to adequately respond to a food challenge. Inadequate 
PPBG regulation occurs quite frequently in patients with 
T2DM, can occur even when metabolic control appears to 
be good, and may represent a separate risk factor for diabetic 
complications (Bonora et al 2006).
The role of therapeutic interventions that speciﬁ  cally 
target PPBG control is a matter of considerable debate 
(Cefalu 2007; Nathan 2007). There is general agreement, 
however, that any intervention that fails to achieve target 
HbA1c goals should be intensiﬁ  ed, and, as discussed above, 
this will frequently require the addition of meal time insulin to 
a basal-only insulin regimen. Several studies have indicated 
that premixed insulin products (ie, products that contain 
both rapid-acting and basal insulin components) may allow 
patients to achieve superior HbA1c control compared to basal-
only regimens (Malone et al 2004, 2005, Raskin et al 2005). 
Regardless of the type of therapy used, successful manage-
ment of BG concentrations has been shown to decrease the 
risk of both the microvascular and macrovascular complica-
tions of T1DM and T2DM (UK Prospective Diabetes Group 
1991; Diabetes Control and Complications Trial Research 
Group 1993; Writing Team for the Diabetes Control and 
Complications Trial 2003; Nathan et al 2005).
For patients with pancreatic β-cell failure and insulin insuf-
ﬁ  ciency, insulin therapy is critical for BG regulation and for 
patient survival. With T2DM, however, the need for insulin 
supplementation usually develops later in the disease process. 
There are a number of therapies other than insulin, including 
oral anti-hyperglycemic medications (OAMs), which are 
available for initial BG control in this population. These medi-
cations include older agents such as the sulfonylureas and met-
formin, used alone or in combination with cholesterol-lowering 
statins, and the insulin-sensitizing thiazolidinediones. One 
newer class of drugs consists of incretin mimetics (glucagon-
like peptide 1 agonists or analogues) and incretin enhancers 
(dipeptidyl peptidase-4 [DPP-4] inhibitors). Incretins are 
gastric hormones that control postprandial hyperglycemia 
by slowing gastric emptying, enhancing glucose-mediated 
insulin release, and controlling elevated postprandial glucagon 
(Blonde et al 2006; Drucker and Nauck 2006). Drugs in this 
class that have received recent United States Food and Drug 
Administration and European Union approval include the 
incretin mimetic Byetta® (exenatide, Amylin Pharmaceuticals, 
San Diego, CA and Eli Lilly and Company, Indianapolis, IN) 
and the DPP-4 inhibitor JanuviaTM (sitagliptin phosphate, 
Merck and Co., Whitehouse Station, NJ). This newer drug 
class shows consistent if moderate reductions in Hb1Ac levels 
in controlled clinical trials (Heine et al 2005; Herman et al 
2005). Weight loss has also been reported with the use of 
Byetta (Buse et al 2007).
Despite the availability of a growing number of treatment 
options for glycemic control in patients with T2DM, most 
patients taking OAMs do not achieve the recommended target 
of HbA1c below 7% (The ACE/ADA Task Force on Inpatient 
Diabetes 2006), let alone the more aggressive goals supported 
by other advisory bodies (Diabetes Medical Guidelines Task 
Force 2002). This group of patients may require insulin treat-
ment to supplement or replace OAMs; however, signiﬁ  cant 
reluctance to initiating insulin therapy has been documented 
in both patients with T2DM and their clinicians. The reasons 
for this reluctance include the fear of needles with anticipated 
pain of daily injections, the inconvenience of injection and 
monitoring regimens, fear of hypoglycemia, perceptions of 
failure in disease progression, and concern about weight gain 
(Zambanini et al 1999; Korytkowski 2002; Richardson and 
Kerr 2003; Peyrot et al 2005; Peyrot et al 2006). Unfortunately, 
delays in initiating insulin therapy in patients with inadequate 
glycemic control can increase the risk of developing serious 
complications (Brown et al 2004).
Overview of inhaled insulin
delivery devices
In the search for alternative routes for systemic delivery of 
insulin, several possibilities have been explored, including Vascular Health and Risk Management 2007:3(6) 951
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nasal, buccal (oral cavity), and pulmonary routes. Of these 
options, the lung, with its highly vascularized and relatively 
permeable large alveolar surface area (~100 m2), currently 
presents the best option for an alternative route for insulin 
delivery. The idea of administering insulin through the lungs 
was ﬁ  rst proposed in 1924 and inhaled delivery of locally 
targeted pharmacological therapies is used routinely (Patton 
2006). However, difﬁ  culties related to bioavailability, for-
mulation and particle size, and the mechanics of deep lung 
protein delivery have, until recently, precluded routine insulin 
inhalation therapy. The impending worldwide epidemic rise 
in diabetes incidence has prompted a resurgence of interest 
in this area. Investigators have established several criteria for 
effective delivery of precise doses of proteins to the systemic 
circulation via the lung. These criteria include an optimal 
aerodynamic particle size, breath holding time, inspiratory 
ﬂ  ow rate, and adequate lung function (Heinemann 2002; 
Patton 2006). The ideal device should deliver a consistent 
insulin dose to the deep lung and be relatively easy and 
convenient to use. An insulin delivery system meeting these 
criteria will increase insulin acceptance by both patients and 
providers, thus facilitating earlier initiation of insulin therapy, 
better BG control, and better treatment outcomes.
There are a number of companies currently developing 
insulin inhalation systems and this rapidly developing ﬁ  eld 
has been the subject of several recent reviews (Mastrandrea 
and Quattrin 2006; Muchmore and Gates 2006; Patton 2006; 
Rosenstock et al 2007a). The only inhaled insulin product 
that currently has marketing authorization is Exubera® 
(Pﬁ  zer/Nektar), but several others, including AERx® iDMS 
(Novo Nordisk), Technosphere® (MannKind) and AIR® 
Inhaled Insulin (Alkermes/Eli Lilly) are being studied in 
Phase 3 clinical trials. These devices use a variety of liquid 
and powder insulin preparations, unique delivery devices 
and unique technical methodologies (Table 1).
Although there is some variability between these different 
insulin inhalation devices in time to peak BG-lowering activ-
ity and duration of activity, they share the common feature 
of rapid onset of activity (10–20 minutes) and relatively 
short duration (Patton 2006). For most of these devices, the 
time to maximal insulin activity is similar to that of rapid-
acting subcutaneous insulin lispro, making them suitable 
for preprandial insulin dosing to control postprandial spikes 
in BG concentration. Recent reports on the clinical evalua-
tion of the efﬁ  cacy of inhaled versus subcutaneous insulins 
are summarized for patients with T1DM in Table 2 and for 
patients with T2DM in Table 3. Overall glycemic control 
was similar between inhaled insulin and subcutaneous 
insulin delivery in most of these studies, with similar safety 
proﬁ  les (discussed below). Importantly, the availability of 
inhaled insulin may promote acceptance of insulin therapy 
in patients with diabetes, which in turn may improve initia-
tion of and compliance with insulin treatment (Freemantle 
et al 2005, 2006).
Safety
Since diabetes is a chronic disease, one important concern 
in the development of inhaled insulin is whether it can be 
used safely over an extended period of time. The major areas 
of concern regarding the safety of long term use involve 
the incidence of low BG concentrations or hypoglycemia, 
increases in circulating anti-insulin antibodies, and changes 
in pulmonary function.
Hypoglycemia
In two recent clinical trials, hypoglycemia occurred less fre-
quently but to a slightly higher degree of severity with inhaled 
insulin compared to subcutaneous insulin in patients with 
T1DM or T2DM (Hollander et al 2004; Quattrin et al 2004; 
Rosenstock et al 2007a). A meta-analysis of 16 open-label 
clinical trials of inhaled insulin in more than 4000 patients 
was recently reported (Ceglia et al 2006). Results of this 
analysis showed that severe hypoglycemia was more likely 
to occur in patients with T2DM using inhaled insulin versus 
those using OAMs alone (risk ratio [RR]: 3.1; conﬁ  dence 
interval [CI]: 1.0–9.1), but that this risk was no greater when 
compared with patients using subcutaneous insulin.
A number of studies have shown that fasting BG is lower 
during inhaled insulin treatment as compared to meal time 
insulin injection regimens (Hollander et al 2004; Quattrin 
et al 2004; Garg et al 2006; Skyler et al 2007). Low fast-
ing BG may increase the risk of nocturnal hypoglycemia, 
although only one publication to date speciﬁ  cally reports 
nocturnal hypoglycemia rates during inhaled insulin treat-
ment (Garg et al 2006). In this report, the rates for any 
hypoglycemia and severe hypoglycemia in patients with 
T1DM were similar between inhaled insulin and injected 
insulin groups. However, better fasting BG levels that 
were achieved with inhaled insulin were associated with 
an increased rate of nocturnal hypoglycemia. This effect 
was observed only among patients who used a rapid acting 
insulin analog during the injection phase of this crossover 
study; patients who used regular human insulin during the 
injection phase did not have this propensity (Garg et al 2006). 
This observation suggests that behavioral guidance regarding 
insulin dosing, meals and snacks, and activity levels may be Vascular Health and Risk Management 2007:3(6) 952
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able to lower the risk of hypoglycemia. Studies using the 
AIR Insulin System to assess the efﬁ  cacy of such behavioral 
modiﬁ  cations are underway.
Anti-insulin antibodies
Administration of exogenous insulin has been associated 
with an increased production of anti-insulin antibodies. These 
increases are common, especially in patients with T1DM. At 
similarly efﬁ  cacious doses, inhaled insulin appears to trigger 
an enhanced production of anti-insulin antibodies compared 
with subcutaneous insulin. However, increased antibody 
levels have not been correlated with adverse events, or with 
relevant clinical correlates of HbA1c levels, insulin dose, 
hypoglycemia, or changes in pulmonary function (Cefalu 
et al 2005; Heise et al 2005; Fineberg et al 2005; Skyler 
et al 2005, 2007). The possible signiﬁ  cance of increases in 
anti-insulin antibodies continues to be assessed in long term 
safety studies.
Pulmonary function
The potential impact of chronic deep-lung deposition of exog-
enous proteins on pulmonary function presents another poten-
tial safety concern. Cough is a common but transient side 
effect of initiating inhaled insulin therapy. Coughing episodes 
were generally described as mild and non-progressive and 
occurred at a similar frequency (∼25%) to those observed in 
patients undergoing other forms of inhalation therapy (Owens 
et al 2006). In the same meta-analysis described above, an 
increased risk of mild-to-moderate, non-progressive cough 
was identiﬁ  ed in patients on inhaled insulin (Ceglia et al 
2006).
However, in short term observational studies, no 
change or only small changes were observed between 
inhaled insulin and other treatment groups in pulmonary 
function tests (PFTs) (Table 2, Table 3) (Weiss et al 
2003; Hermansen et al 2004; Rosenstock et al 2005; 
Cefalu et al 2006). When patients using inhaled insulin 
were followed for up to 2 years, changes in lung func-
tion from baseline were small when measured by forced 
expiratory volume in 1 second (FEV1,  1%) and carbon 
monoxide diffusing capacity (DLCO,  2%), the two most 
widely accepted indices of pulmonary function (Skyler 
et al 2007). These changes occurred within the first 3 
months of initiating treatment and were not progressive. 
Current recommendations for the only marketed inhaled 
insulin dictate that all patients initiating inhaled insulin 
therapy undergo baseline PFTs that include spirometry 
and assessment of FEV1 values. Inhaled insulin should 
not be used in patients whose FEV1 is below 70% of 
predicted values. It is also recommended that patients 
should be reassessed after 6 months and yearly thereafter, 
and that use of inhaled insulin should be discontinued if 
Table 1 Current insulin inhalation systems
Phase Name  Developer  (partner)  Delivery  system
Marketed* Exubera®  Nektar Therapeutics  Dry-powder, single-dose blister packs
   (Pﬁ  zer Inc.)  (1–3 mg); breath actuated inhaler
Phase III  AIR®  Alkermes  Dry-powder phospholipid matrix; 
    (Eli Lilly)   small mechanical and breath-actuated inhaler
 AERx® iDMS  Aradigm   Liquid aerosol; patient guided by
    (Novo Nordisk)   microprocessor feedback inhaler system
 Technosphere®  MannKind  Dry-powder, encapsulated in
      microspheres with diketopiperzine
      derivative; breath-actuated inhaler
Phase II  Inhaled Insulin  Abbott Laboratories/KOS   Crystalline, breath-actuated
   Pharmaceutical propellant  inhaler
Phase I  Microdose Dry   Qdose Ltd. (Microdose   Dry-powder; breath actuated,
  Powder Inhaler  Technology)  electronically controlled inhaler
  ProMaxx   Baxter Biopharma  Dry-powder microsphere; propellant
  Microspheres    metered-dose inhaler and
      two types of dry-powder inhalers:
      Cyclohaler and Disphaler
 AlveairTM  CoreMed  Liquid aerosol polymer/bio-adhesive
     formulation
  BioAir  BioSante Pharmaceuticals  Coated dry particles
*Marketing authorization in Europe and the USA (2006).Vascular Health and Risk Management 2007:3(6) 953
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PFT values decrease by more than 20% (Exubera pack-
age insert).
Attributes and efﬁ  cacy of the AIR 
Insulin System
The AIR Insulin System is comprised of three elements: AIR 
Inhaled Insulin, the AIR Insulin Inhaler, and the Directions 
for Use circular. AIR Inhaled Insulin is composed of a 
combination of rDNA native human insulin and an excipient 
based on a normal component of alveolar surfactant. AIR 
Inhaled Insulin is packaged as a dry powder in capsules 
designed to deliver doses approximately equivalent to either 
2 U (0.9 mg capsule ﬁ  ll weight of insulin) or 6 U (2.6 mg 
capsule ﬁ  ll weight of insulin) of injected insulin. The two 
strengths provide dosing ﬂ  exibility for individual patients. 
A higher dose formulation is currently undergoing clinical 
testing.
The AIR Insulin System incorporates unique features for 
pulmonary delivery of pharmaceutical products. The tech-
nology is based upon the inhalation of dry-powder aerosols 
composed of relatively large low-density particles. Individual 
particles contain both the active agent and an excipient dis-
persed throughout the particle. Even though the particles 
have a relatively large geometric size (median   5 μm), their 
Table 2 Summary of published efﬁ  cacy and/or safety studies in patients with type 1 diabetes (T1DM)
  Study description     Glycemic control  Safety
Clinical development  Duration  Evaluable   INH vs  HbA1c (%)  FEV1 (L)a
stage   subjects  (n)  comparator 
Phase III          
(Skyler et al 2007)  24 months  n = 580  Exubera® vs SC insulin    –0.051 vs –0.034*b
        [4.0 vs 3.8]  [–0.437 vs –0.287]
        
(Skyler et al 2005)  6 months  n = 328  Exubera® + NPH vs  –0.3 vs –0.1  –0.016 vs 0.008
     REG  + NPH  [9.3 vs 9.9*]  [–0.750 vs –0.229*] 
        
(Dumas et al 2005)  24 weeks  n = 226  Exubera® vs SC mixed  –0.4 vs –0.5  –0.070 vs –0.027
        [6.8 vs 5.5*]  [–0.973 vs –0.246]
        
(Fineberg et al 2005)  2-year extension  n = 1353   Exubera® vs SC  No correlation   No correlation between
  (pooled trials)     insulin  between antibodies   antibodies and lung function
        and glycemic control 
        
(Quattrin et al 2004)  6 months  n = 334  Exubera® vs SC insulin  –0.2 vs –0.4  –0.065 vs 0.002 
        [8.6 vs 9.0*]  [–1.685 vs –0.031*]
        
(Rosenstock et al 2004)  1 year  n = 102  Exubera® vs SC insulin  –0.78 vs –1.06  –0.03 vs 0.02 
  (extension)    (in both T1DM and T2DM)  [2.52 (INH)]  [–1.05 vs –2.53]
(Skyler J for the Exubera  4 years   n = 112  Exubera® 4th year vs  –0.48 (INH)  –0.057 (non-INH, –0.071)
Phase 2 Study Group 2004)  (extension)    Exubera® baseline  [1.5 vs 2.58]  [–0.376 (non-INH, –0.673)]
(Barnett AH for the Exubera  12 months   n = 627  Exubera® +  –2.0 vs –1.8  NS 
Phase III Study Group 2004)  (extension)    OA vs OA(s)  [NS]  [NS]
Phase II
(Garg et al 2006)  12 weeks  n = 259  AIR® vs SC insulin +  –0.2 vs –0.1  NA
      insulin glargine  [7.9 vs 7.7]  [–1.6 vs –0.6†]
(Heise et al 2005)  24 weeks  n = 47  Exubera® vs SC insulin  No correlation   NA
       between  antibodies 
        and glycemic control 
(Skyler et al 2001)  12 weeks  n = 72  Exubera® vs SC insulin  –0.6 vs –0.8  –2.17 vs –1.02
        [33 vs 31]  [–5.78 vs –7.71]
aReported treatment differences in values for HbA1c [overall hypoglycemia (events/subject months)] and for FEV1 [changes (in liters) from baseline in DLco (ml/min/mmHg)].
bThe signiﬁ  cant difference between treatment groups in FEV1 developed during the ﬁ  rst 3 months and was nonprogressive thereafter.
*p   0.05 [also for data expressed as 95% conﬁ  dence interval (CI)].
†p   0.001.
Abbreviations: HbA1c, glycosylated hemoglobin; INH, inhaled insulin; NA, (data) not available; NPH, neutral protamine Hagedorn insulin; NS, not signiﬁ  cant (reported as ‘no 
difference’, values not provided); OA, oral antidiabetic agents; REG, regular human insulin; ROS, rosiglitazone; UL, ultralente insulin.Vascular Health and Risk Management 2007:3(6) 954
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low density ( 0.4 g/mL) results in an effective aerodynamic 
particle with a diameter range affords access to the deep lung. 
Relative to standard inhalation aerosols, the larger and less 
dense AIR Insulin particles require less energy to disperse 
prior to delivery to the lungs. This relatively low agglomeration 
and high dispersability permit efﬁ  cient delivery of both small 
and large drug doses to the deep lung in a single inhalation 
from a simple, breath-actuated inhaler (Edwards et al 1997, 
1998). Once deposited in the lung, the particles provide rapid 
and reliable uptake of protein therapeutics into the systemic 
circulation.
The AIR Insulin Inhaler is a small, hand-held, dry powder 
device that is capsule-based and breath-actuated (Rosenstock 
et al 2007a). It is designed such that the appropriate aerosol 
dose is delivered to the patient using the energy derived 
from a single inhalation of modest intensity. The inhaler 
Table 3 Summary of published efﬁ  cacy and/or safety studies in patients with type 2 diabetes (T2DM)
  Study description    Glycemic control  Safety
Clinical development  Duration  Evaluable  INH vs comparator  HbA1c (%)a   FEV1 (L)a [DLco
stage    subjects (n)    [Overall hypoglycemia  (ml/min/mmHg)a]
       (events/subject  months)] 
Phase III       
(Barnett et al 2006a)  24 weeks  n = 414  Exubera + metformin vs  –2.12 vs –2.05  –0.09 vs –0.04
     glibenclamide  +  [0.18 vs 0.08]  [–0.43 vs –0.78]
     metformin   
(Barnett et al 2006b)  24 weeks  n = 423  Exubera + sulphonylurea  –2.06 vs –1.83*  –0.07 vs –0.04
     vs  metformin  +   [0.31 vs 0.17]  [–0.27 vs 0.05]
     sulphonylurea   
(Cefalu et al 2005)  2 years  n = 304  Exubera® + OA vs OAb  –1.8 vs –1.50   –0.077 vs –0.67
        [0.120 vs 0.148]  [–0.703 vs – 0.735]
(DeFronzo et al 2005)  3 months  n = 143  Exubera® vs   –2.3 vs –1.4*  –0.016 vs – 0.001
      rosiglitazone  [0.7 vs 0.05]  [–0.973 vs – 0.829]
(Hollander et al 2004)  6 months  n = 298  Exubera® + UL vs  –0.7 vs –0.6  –0.05 vs –0.91
     REG  + NPH  [1.4 vs 1.6*]  [–0.79 vs –0.71]
(Rosenstock et al 2005)  3 months  n = 309  Exubera® vs Exubera® +  –1.4† vs –1.9† vs –0.2  –0.002 and –0.028d
      OA vs OA  [1.7 vs 1.3 vs 0.1]  [–0.388 and –0.303]
(Skyler J for the Exubera  4 years   n = 112c Exubera® 4th year vs  –0.48  –0.057 (non-INH,
Phase 2 Study Group 2004)  (extension)    Exubera® baseline  [1.5 vs 2.58]  –0.071) [–0.376 
          (non- INH, –0.673)]
Phase II
(Rosenstock et al 2006)  4 weeks  n = 102  AIR Insulin standard vs  PPBG –0.11 vs   –0.12 vs –0.08
      intensive training  0.23  [–1.01 vs –1.83]
(Rosenstock J et al 2005)  12 weeks  n = 119  Technosphere   –0.76 vs –0.32‡ ND
      vs placebo  [NS (no events)]  [NS]
(Cefalu et al 2005)  3 months  n = 26  Exubera® + UL vs  –0.71* (INH)  NA
     baseline  injection  [0.83]  [NA]
      regimen of 2–3   
     injections/day   
(Hermansen et al 2004)  12 weeks  n = 107  AERx® iDMS vs  –0.69 vs –0.77  –3.2 vs –3.5
      SC insulin  [1.05 vs 1.52]  [–2.0 vs –1.1]
(Weiss et al 2003)  12 weeks  n = 107  AERx®- iDMS + NPH  –2.3 vs –0.1‡  –0.09 vs –0.03
      (HS) vs SC   [0.64 vs 0.06‡]  [–1.10 vs –1.26]
     Actrapid  +    
     NPH(HS)  insulin   
aReported values are changes from baseline except where italicized (treatment difference).
bOnly the two controlled studies are reported here.
cData derived from pooled T1DM and T2DM patients.
dMean treatment differences: Exubera vs OA and Exubera + OA vs OA, respectively.
*p   0.05 [also for data expressed as 95% conﬁ  dence interval (CI)].
†p   0.001.
‡p < 0.0001.
Abbreviations: HbA1c, glycosylated hemoglobin; HS, at bedtime; INH, inhaled insulin; NA, (data) not available; NPH, neutral protamine Hagedorn insulin; NS, not signiﬁ  cant 
(reported as ‘no difference’, values not provided); OA, oral antidiabetic agents; REG, regular human insulin; UL, ultralente insulin.Vascular Health and Risk Management 2007:3(6) 955
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is a passive device with moderate resistance to inspiratory 
ﬂ  ow, which invites patients to inhale at a moderate rate in 
order to optimize deep lung deposition. Delivery of a similar 
powder based on the AIR technology has been characterized 
in vivo by high and reproducible emitted doses (87%) and 
high lung deposition (51% of the total dose) independent of 
peak inspiratory ﬂ  ow rate across a broad range (12–86 L/min) 
(DeLong et al 2005).
The AIR Insulin System is currently undergoing Phase 
III clinical testing, including long-term (24-month) safety 
and efﬁ  cacy studies in patients with T1DM or T2DM, and 
additional safety evaluations in patients with comorbid 
lung disease and diabetes. Other studies that compare the 
efﬁ  cacy and safety of AIR Insulin to monotherapy with 
insulin glargine are also underway. These studies, along with 
information on HbA1c from early phase clinical trials with AIR 
insulin, are described in separate reviews (Muchmore and 
Gates 2006; Rosenstock et al 2007a).
Patient training, satisfaction
and preference for inhaled insulin 
therapy
Some of the reported barriers to strict glycemic control in 
patients with diabetes include reluctance to initiate insulin 
therapy and poor patient adherence because of pain and fear 
of injection, inconvenience, and social stigma associated with 
injections. Satisfaction surveys assessing the ﬂ  exibility and 
ease of use, pain, side effects, and social acceptance of inhaled 
insulin have been overwhelmingly favorable (Hollander et al 
2004; Quattrin et al 2004; Hayes et al 2007a). In patients 
with either T1DM or T2DM who have previously used sub-
cutaneous insulin for diabetes management, 80% preferred 
inhaled insulin over conventional subcutaneous insulin for 
their meal time insulin therapy (Rosenstock et al 2004). In a 
recent report of self-directed versus intensive patient training 
for use of the AIR Insulin Inhaler, it was found that patients 
can be self-directed without detrimental effects on metabolic 
(Rosenstock et al 2007b) or patient-reported (Hayes et al 
2007b) outcomes, including measures of vitality, diabetes-
associated symptoms, fear of hypoglycemia, and insulin-
delivery system satisfaction. These data support the AIR 
Insulin Inhaler as a patient-friendly insulin delivery method 
that should appeal to both clinicians and patients. Impor-
tantly, this sufﬁ  ciency of patient-directed training should 
allow precious diabetes education resources to be deployed 
in other important aspects of diabetes care beyond teaching 
the mechanics of inhaled insulin administration.
Contraindications to the use
of inhaled insulin
There are several patient populations for whom the use of 
inhaled insulin is not recommended. Women who are preg-
nant should not use it, and its use has not been approved for 
children or adolescents. Current tobacco smokers or patients 
who have smoked in the preceding six months are also not 
candidates for inhaled insulin. Smoking has been shown to 
increase the rate and extent of inhaled insulin absorption 
(Himmelmann et al 2003; Becker et al 2006; Pan et al 2007), 
while acute passive exposure to smoke decreases the rate 
and extent of absorption (FDA Endocrinologic and Meta-
bolic Drugs Committee 2005). Smoking cessation, nicotine 
replacement therapy, and acute smoking re-exposure are also 
associated with clinically signiﬁ  cant alterations in inhaled 
insulin pharmacokinetics and glucodynamics (Pan et al 
2007). Thus smokers or former smokers at risk of recidivism 
should not use inhaled insulin.
Patients with compromised lung function, such as those 
with asthma or chronic obstructive pulmonary disease (COPD), 
are also not candidates for Exubera, the inhaled insulin that is 
currently marketed, due to unpredictable absorption rates and 
possible problems with simultaneous use of bronchodilators 
(Exubera package insert). AIR Inhaled Insulin was recently 
reported to be well tolerated by patients with COPD, and to 
elicit time-exposure and time-action proﬁ  les similar to subcu-
taneous insulin lispro (Rave et al 2007). However, there was 
reduced insulin absorption and decreased metabolic effects 
when this population was compared with healthy subjects. 
Clinical evaluations of the use of inhaled insulins in these 
populations are ongoing (Rosenstock et al 2007a).
Summary and conclusions
Diabetes is a signiﬁ  cant worldwide health problem. Insulin 
resistance and deregulated BG control are established risk 
factors for microvascular complications and cardiovascular 
disease, with risk reduced by adequate BG control and inten-
sive diabetes therapy. Despite the availability of a variety of 
medications for BG regulation, most patients do not achieve 
optimal BG control. Inhaled insulin is a new, safe means to 
deliver insulin that may increase patient compliance with 
insulin therapy, helping them to achieve optimal glycemic 
control and possibly reducing their risk of developing car-
diovascular complications. However, diabetes is a chronic 
illness requiring lifetime intervention. Thus, long term studies 
are still required in order to ensure the continued efﬁ  cacy and 
safety of this new treatment for diabetes.Vascular Health and Risk Management 2007:3(6) 956
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